Listen to SCN2A Insights each month for the latest on SCN2A and genetic epilepsy
Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders. By interviewing leading researchers and others working in the field, you will hear directly from them about their research and be better informed.
Hosted by Kris Pierce, and David Cunnington, parents of Will, who has SCN2A.
- Subscribe and leave us a review via Apple Podcasts
- You can also find SCN2A Insights on Spotify, Google Podcasts and Omny.fm
- Or search for ‘SCN2A Insights’ in your favourite podcast app
- Contact us via email
What is the relationship between loss of function SCN2A mutations and autism? What can SCN2A mutations teach us about mechanisms underpinning autism?
Why are models needed to assess and develop treatments in rare diseases? What types of models are there? When are different models used?
What should you expect when you attend a genetic epilepsy clinic? What happens when you need to transition from paediatric to adult care?
Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work?
Genetic testing is complex. To decipher some of the terminolgy and help explain the process we talked to Dr Emma Palmer, Clinical Geneticist.
Children with developmental disabilities can have touble with sleep. Assoc Prof Margot Davey discusses what can be done to improve sleep in these children.
CURE Epilepsy has raised more than $60 million to fund epilepsy research. We talk with Dr Laura Lubbers about the work CURE Epilepsy is doing.
Working collaboratively has been one of the hallmarks of Prof Daniel Lowenstein’s career and has led to breakthrough research.
We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.
When Alex Nemiroff's son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.